Key takeaways
- Both manufacturers now publish cash prices directly. Novo Nordisk lists Wegovy self-pay at $349 per month for the pen at 0.25 mg through 2.4 mg (wegovy.com, checked August 2026), and Eli Lilly lists Zepbound single-dose vials at $299 to $449 per month depending on dose (zepbound.lilly.com, checked August 2026).
- The dose changes the price. These medicines escalate over months, and both companies price by strength, so the first month is the cheapest month.
- Insurance is the single biggest variable. In the KFF Health Tracking Poll released on 14 November 2025, 56% of GLP-1 users said the drugs were difficult to afford, including 55% of those with insurance.
- Compounded versions are not FDA approved. They are often cheaper. That is a real trade-off and it should be discussed openly, not buried in a price list.
- Medication price is not programme price. Consultation, monitoring and laboratory work are separate almost everywhere, including here.
- This page is education, not medical advice. Whether a GLP-1 is appropriate for you is a clinical decision made with a prescriber.
How much does a GLP-1 weight loss medication cost per month?
Paying cash, the manufacturers' own published self-pay prices in August 2026 run from $149 per month for the oral form of Wegovy up to $699 per month for the highest doses of the Zepbound KwikPen at Eli Lilly's regular self-pay price. Most people paying cash for an injectable land between $299 and $449 per month. Those are medication prices only, and they do not include the consultation, the monitoring or any laboratory work.
That is a far narrower band than it was two years ago, and the reason is straightforward: in late 2025 both manufacturers cut their direct-to-consumer prices sharply. Novo Nordisk's news release of 17 November 2025 described lowering the self-pay price of Wegovy from $499 to $349 per month. Eli Lilly cut the price of Zepbound single-dose vials at the beginning of December 2025. Anyone quoting you a figure from 2024 is quoting a market that no longer exists.
What do Novo Nordisk and Eli Lilly actually charge if you pay cash?
Both companies publish their cash prices on their own patient websites, which makes them the most reliable figures available. The table below reproduces those published prices exactly as they stood when we checked them on 11 August 2026.
| Product and dose | Published self-pay price | Source |
|---|---|---|
| Wegovy pen, 0.25 mg to 2.4 mg | $349 per month | Novo Nordisk, wegovy.com |
| Wegovy HD pen, 7.2 mg | $399 per month | Novo Nordisk, wegovy.com |
| Wegovy pen, first two months at 0.25 mg or 0.5 mg (introductory offer) | $199 per month | Novo Nordisk, wegovy.com |
| Wegovy oral, 1.5 mg and 4 mg | $149 per month | Novo Nordisk, wegovy.com |
| Zepbound single-dose vial, 2.5 mg | $299 per month | Eli Lilly, zepbound.lilly.com |
| Zepbound single-dose vial, 5 mg | $399 per month | Eli Lilly, zepbound.lilly.com |
| Zepbound single-dose vial, 7.5 mg to 15 mg | $449 per month | Eli Lilly, zepbound.lilly.com |
| Zepbound KwikPen, regular self-pay, 7.5 mg | $499 per month | Eli Lilly, zepbound.lilly.com |
| Zepbound KwikPen, regular self-pay, 10 mg to 15 mg | $699 per month | Eli Lilly, zepbound.lilly.com |
Both programmes attach conditions. Novo Nordisk's introductory price applies only to the first two fills at the two lowest doses, and its oral pricing carries its own offer dates. Eli Lilly defines a one-month fill as 28 days, or four vials for the single-dose option, and its self-pay pricing runs through the Zepbound Self Pay Journey Program rather than through a pharmacy benefit. Read the programme terms on the manufacturer's own site before you rely on any of these figures.
Why is the price of semaglutide and tirzepatide so different from one clinic to the next?
Four things move the number: whether you are using insurance or paying cash, which dose you are on, whether the product is the FDA-approved brand or a compounded version, and how much clinical care is bundled into the price. A quote that looks unusually low is usually excluding something, and the thing it excludes is most often the monitoring.
Those four variables compound. Two people can both be taking tirzepatide, in the same county, in the same month, and pay wildly different amounts, because one plan covers obesity medication and the other excludes it. Neither is being cheated. They are on different sides of a coverage line that has nothing to do with clinical need.
Does insurance cover semaglutide or tirzepatide for weight loss?
Sometimes, and it depends entirely on the plan. Many plans cover these medicines for type 2 diabetes but exclude them for weight loss, and plans that do cover weight loss often require prior authorisation and documented criteria. In the KFF Health Tracking Poll released on 14 November 2025, 27% of insured GLP-1 users said they paid the full cost themselves, and 14% of users said they stopped taking the medication because of cost.
The same KFF poll found that 56% of everyone who had taken a GLP-1 said the drugs were difficult to afford, including 55% of those who had insurance. That second figure is the important one. Having coverage is not the same as the medicine being affordable, and a plan that covers the drug may still leave a substantial share with you.
The practical step is unglamorous but worth an afternoon: call the number on the back of your insurance card, ask specifically whether your plan covers GLP-1 medication for weight management as opposed to diabetes, and ask what the prior authorisation criteria are.
Why does the cost go up as the dose goes up?
Because these medicines are dosed by escalation, and both manufacturers price by strength. On Eli Lilly's published self-pay pricing for the Zepbound single-dose vial, a one-month fill is $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg upward. The practical lesson is to budget for the maintenance dose rather than the starting dose, because the starting dose is the cheapest month you will have.
This is the most common budgeting mistake we see. Somebody prices the programme on the starting dose, commits, then finds a few months later that the monthly figure has moved. Escalation is deliberate and slow, because escalating quickly is what makes people feel unwell. It is a clinical decision with a cost consequence you should see coming.
Novo Nordisk prices Wegovy differently, holding a single self-pay figure across doses 0.25 mg through 2.4 mg. If predictability matters more to you than the lowest possible starting figure, that flat structure is worth weighing. We compare how the two medicines differ clinically on our semaglutide versus tirzepatide page.
Is compounded semaglutide cheaper than the brand?
It is often advertised at a lower monthly price, but compounded semaglutide and tirzepatide are not FDA approved. The FDA's position is that compounded drugs do not go through its premarket review for safety, effectiveness or quality, and that they therefore carry more risk than FDA-approved products. The FDA has also proposed excluding semaglutide, tirzepatide and liraglutide from the list of bulk substances that outsourcing facilities may compound from. That is a decision to make with a prescriber, with the regulatory status openly on the table.
None of that means every compounded product is dangerous, or that no prescriber should ever consider one. It means the price difference is not free, and anybody quoting a compounded price without mentioning any of this is leaving out the part that matters.
What is usually left out of an advertised GLP-1 price?
Commonly: the initial consultation, follow-up visits, laboratory work, the price change at each dose increase, and any charge for switching medicines if the first one does not suit you. Ask whether the advertised figure is the medication alone or the whole programme, and ask what the monthly figure becomes at a maintenance dose rather than at the starting dose.
One more omission is worth naming, because it is the expensive one. A programme priced purely on shipping a medication has no line item for the visit where somebody notices that your blood pressure has drifted, that a fortnight of poor intake has left you dehydrated, or that what you are calling ordinary nausea is not ordinary. A price that does not include those visits is not cheaper. It is smaller.
